Compare Heron Therapeutics Inc (HRTX) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Synchrony Financial — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Synchrony Financial trades at $72.9 (market cap $23.99B). The key difference: Synchrony Financial is far larger — about 352.7× Heron Therapeutics Inc's market cap, and Synchrony Financial pays a 1.84% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Synchrony Financial for 29 Days on average.
| HRTX | SYF | |
|---|---|---|
Market Cap | $68.01M | $23.99B |
Volume | 1,891,941 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $1.49 | $88.47 |
52-Week Low | $0.27 | $63.78 |
Typical Hold Time | 35 Days | 29 Days |
Enterprise Value | $174.75M | $24.23B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
Synchrony Financial (SYF) trades at $72.87, up 1.31% with bullish technical signals despite mixed momentum indicators. The stock shows strong fundamentals with a low P/E of 7.56, robust ROE of 22.23%, and consistent earnings beats. Recent partnerships with OpenAI and Vetspire highlight strategic growth initiatives in AI-driven commerce and veterinary financing.
SYF presents compelling value with attractive valuation metrics and strong profitability, though investors face risks from consumer credit quality and competitive pressures. Analyst consensus targets $87.58 (20% upside) with 61% buy ratings, supporting a positive outlook if the company maintains its earnings trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
